JP2020531002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531002A5 JP2020531002A5 JP2020507675A JP2020507675A JP2020531002A5 JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5 JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- igg
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims 120
- 150000001413 amino acids Chemical group 0.000 claims 76
- 235000001014 amino acid Nutrition 0.000 claims 68
- 238000006467 substitution reaction Methods 0.000 claims 62
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 235000018102 proteins Nutrition 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 235000004279 alanine Nutrition 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 11
- 239000004473 Threonine Substances 0.000 claims 11
- 241000283073 Equus caballus Species 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 9
- 239000000833 heterodimer Substances 0.000 claims 9
- 241000282326 Felis catus Species 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 241000282465 Canis Species 0.000 claims 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- 241000282324 Felis Species 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000282327 Felis silvestris Species 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000004474 valine Chemical group 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545858P | 2017-08-15 | 2017-08-15 | |
| US62/545,858 | 2017-08-15 | ||
| PCT/IB2018/056142 WO2019035010A1 (en) | 2017-08-15 | 2018-08-15 | IGG VARIANTS FOR VETERINARY USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531002A JP2020531002A (ja) | 2020-11-05 |
| JP2020531002A5 true JP2020531002A5 (cg-RX-API-DMAC7.html) | 2021-09-30 |
Family
ID=65361820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507675A Pending JP2020531002A (ja) | 2017-08-15 | 2018-08-15 | 獣医学用ｉｇｇ ｆｃ変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12297272B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3668536A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020531002A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200057701A (cg-RX-API-DMAC7.html) |
| CN (2) | CN111182915A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018318440A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020002871A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3071337A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020001707A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019035010A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019011860A2 (pt) | 2016-12-09 | 2019-11-12 | Akston Biosciences Corp | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune |
| WO2019035010A1 (en) | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | IGG VARIANTS FOR VETERINARY USE |
| SI4186920T1 (sl) | 2018-06-29 | 2024-05-31 | Akston Biosciences Corporation | Ultra dolgo delujoči inzulin-FC fuzijski proteini in postopki uporabe |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| MX2021004313A (es) * | 2018-10-18 | 2021-05-27 | Kindred Biosciences Inc | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. |
| US20220064263A1 (en) * | 2018-12-27 | 2022-03-03 | Kindred Biosciences, Inc. | IGG FC Variants for Veterinary Use |
| US11542333B2 (en) * | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| BR112021018156A2 (pt) * | 2019-03-20 | 2021-11-16 | Kindred Biosciences Inc | Antagonistas de ngf para uso médico |
| EP4004035A4 (en) * | 2019-07-30 | 2023-06-28 | Kindred Biosciences, Inc. | Parvovirus antibodies for veterinary use |
| CA3159486A1 (en) | 2019-12-19 | 2021-06-24 | Thomas M. Lancaster | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| JP2023513952A (ja) | 2020-02-19 | 2023-04-04 | アディボ ゲーエムベーハー | 改変Ｆｃ領域 |
| WO2021188631A1 (en) * | 2020-03-18 | 2021-09-23 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
| WO2021207599A1 (en) | 2020-04-10 | 2021-10-14 | Akston Biosciences Corporation | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CA3173864A1 (en) * | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Long-acting anti-il31 antibodies for veterinary use |
| GB202005879D0 (en) * | 2020-04-22 | 2020-06-03 | Petmedix Ltd | Heterodimeric proteins |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CN115867572B (zh) | 2020-05-11 | 2025-06-06 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| EP4178977A1 (en) | 2020-07-10 | 2023-05-17 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| US20230405150A1 (en) * | 2020-08-24 | 2023-12-21 | The Trustees Of The University Of Pennsylvania | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines |
| CN112625093B (zh) * | 2020-12-29 | 2022-12-23 | 清远市图微安创科技开发有限公司 | 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物 |
| EP4373861A4 (en) | 2021-07-23 | 2025-08-20 | Akston Biosciences Corp | INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER |
| CN117940455A (zh) * | 2021-08-06 | 2024-04-26 | 佩特迈迪有限公司 | 抗体Fc变体 |
| EP4642796A2 (en) | 2022-12-27 | 2025-11-05 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| GB202311984D0 (en) * | 2023-08-04 | 2023-09-20 | Petmedix Ltd | Optimised fc molecules |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
| US7297482B2 (en) * | 1998-10-08 | 2007-11-20 | Rigel Pharmaceuticals, Inc. | Structurally biased random peptide libraries based on different scaffolds |
| ATE480558T1 (de) * | 1999-12-23 | 2010-09-15 | Univ Geneve | Auf scf peptid basiertes basolaterales sortiersignal und inhibitoren dafür |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| JP2004321100A (ja) | 2003-04-25 | 2004-11-18 | Rikogaku Shinkokai | ＩｇＧのＦｃ領域を含むタンパク質の変異体 |
| UA87458C2 (ru) | 2003-06-12 | 2009-07-27 | Елі Ліллі Енд Компані | Гибридные белки-аналоги glp-1 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1831252B1 (en) | 2004-12-22 | 2009-07-01 | Eli Lilly And Company | Glp-1 analog fusion protein formulations |
| WO2006105062A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| US8658174B2 (en) * | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| NZ582480A (en) | 2007-07-10 | 2011-03-31 | Lilly Co Eli | Glp-1-fc fusion protein formulation |
| EP3318573A1 (en) * | 2008-12-23 | 2018-05-09 | F. Hoffmann-La Roche AG | Mmunoglobulin variants with altered binding to protein a |
| WO2010117760A2 (en) | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| JP2013523098A (ja) | 2010-03-29 | 2013-06-17 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| CA2835094C (en) | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| WO2012153123A1 (en) | 2011-05-06 | 2012-11-15 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| CN103930134B (zh) | 2011-07-18 | 2016-12-21 | 阿茨生物股份有限公司 | 长效促黄体激素(lh)化合物 |
| AU2012285475B2 (en) | 2011-07-19 | 2017-09-14 | The National Institute For Biotechnology In The Negev, Ltd. | Novel IL-17R-ECD mutants |
| BR112014010008A2 (en) | 2011-10-26 | 2018-09-04 | Novartis Ag | monoclonal antibodies, their uses and nucleic acids |
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| HK1201541A1 (en) * | 2012-02-22 | 2015-09-04 | Nexvet Australia Pty Ltd | Tumour necrosis factor receptor fusion proteins and methods of using the same |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| WO2014093387A1 (en) | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| KR20160034404A (ko) | 2013-07-31 | 2016-03-29 | 암젠 인크 | Ｆc-함유 폴리펩타이드의 안정화 |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| AU2014368449C1 (en) | 2013-12-20 | 2021-05-06 | Intervet International B.V. | Canine antibodies with modified CH2-CH3 sequences |
| EP3104887A4 (en) | 2014-02-11 | 2017-03-15 | Beijing Advaccine Biotechnology Co. Ltd. | Vaccines with interleukin-17 as an adjuvant |
| WO2016044189A1 (en) | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
| CN107074952B (zh) | 2014-09-30 | 2021-04-09 | 英特维特国际股份有限公司 | 结合犬pd-l1的pd-l1抗体 |
| EP3842453A1 (en) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and protein a-binding properties |
| KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| TWI719970B (zh) | 2015-03-23 | 2021-03-01 | 美商永斯醫療股份有限公司 | 針對ｉｃｏｓ之抗體 |
| WO2017068472A1 (en) | 2015-10-19 | 2017-04-27 | Novartis Ag | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
| EP3390451B1 (en) | 2015-12-18 | 2025-01-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| AU2017212534A1 (en) | 2016-01-26 | 2018-07-26 | Defensin Therapeutics Aps | Methods for modulating intestinal microbiota |
| AU2017219596B2 (en) | 2016-02-18 | 2019-07-04 | Elanco Us Inc. | Chimeric canine anti-CD20 antibody |
| US12281154B2 (en) | 2016-05-20 | 2025-04-22 | President And Fellows Of Harvard College | Gene therapy methods for age-related diseases and conditions |
| CN110267674A (zh) | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
| CN110114369A (zh) | 2016-10-17 | 2019-08-09 | 威隆股份公司 | 修饰的抗体恒定区 |
| EP3548073A4 (en) | 2016-12-02 | 2020-07-22 | The Texas A&M University System | FUSION PROTEINS FOR THE SELECTIVE DEPREVIRANT OF ANTIBODIES SPECIFIC TO AN ANTIGEN |
| AU2018254542B2 (en) * | 2017-04-21 | 2022-12-22 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| CA3065553A1 (en) | 2017-06-18 | 2018-12-27 | Kindred Biosciences, Inc. | Il17a antibodies and antagonists for veterinary use |
| WO2019035010A1 (en) | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | IGG VARIANTS FOR VETERINARY USE |
| SI4186920T1 (sl) | 2018-06-29 | 2024-05-31 | Akston Biosciences Corporation | Ultra dolgo delujoči inzulin-FC fuzijski proteini in postopki uporabe |
| AU2019338602A1 (en) | 2018-09-14 | 2021-04-01 | Elanco Us Inc. | Anti-IL4 receptor antibodies for veterinary use |
| MX2021004313A (es) | 2018-10-18 | 2021-05-27 | Kindred Biosciences Inc | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. |
| EP3870601A4 (en) | 2018-10-25 | 2022-07-13 | Kindred Biosciences, Inc. | IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE |
| CN113227134A (zh) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | 抗体的Fc区变体 |
| AU2019397516A1 (en) | 2018-12-12 | 2021-06-17 | Elanco Us Inc. | Erythropoietin analogs for veterinary use |
| US20220064263A1 (en) | 2018-12-27 | 2022-03-03 | Kindred Biosciences, Inc. | IGG FC Variants for Veterinary Use |
| US11542333B2 (en) | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| BR112021018156A2 (pt) | 2019-03-20 | 2021-11-16 | Kindred Biosciences Inc | Antagonistas de ngf para uso médico |
| MX2022002171A (es) | 2019-08-22 | 2022-05-13 | Cidara Therapeutics Inc | Dominios fc variantes y usos de estos. |
| CN114364796B (zh) | 2019-09-02 | 2023-07-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| MX2022012866A (es) | 2020-04-17 | 2022-11-08 | Zoetis Services Llc | Variantes de anticuerpos caninos. |
| MX2022012793A (es) | 2020-04-17 | 2022-11-07 | Zoetis Services Llc | Variantes de anticuerpos felinos. |
| CA3173864A1 (en) | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Long-acting anti-il31 antibodies for veterinary use |
| CA3173927A1 (en) | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Il4/il13 receptor molecules for veterinary use |
| CN115867572B (zh) | 2020-05-11 | 2025-06-06 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| EP4166574A4 (en) | 2020-06-10 | 2025-01-15 | Bica Therapeutics Inc. | FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE |
| EP4172193A1 (en) | 2020-06-29 | 2023-05-03 | Zoetis Services LLC | Feline antibody variants for improving stability |
| EP4178977A1 (en) | 2020-07-10 | 2023-05-17 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| WO2022046941A1 (en) | 2020-08-26 | 2022-03-03 | Angiex, Inc. | Antimitotic tetrapeptide-antibody conjugates and methods of using same |
-
2018
- 2018-08-15 WO PCT/IB2018/056142 patent/WO2019035010A1/en not_active Ceased
- 2018-08-15 AU AU2018318440A patent/AU2018318440A1/en not_active Abandoned
- 2018-08-15 BR BR112020002871-1A patent/BR112020002871A2/pt unknown
- 2018-08-15 CN CN201880064650.9A patent/CN111182915A/zh active Pending
- 2018-08-15 KR KR1020207005513A patent/KR20200057701A/ko not_active Ceased
- 2018-08-15 CN CN202411340586.6A patent/CN119390821A/zh active Pending
- 2018-08-15 CA CA3071337A patent/CA3071337A1/en active Pending
- 2018-08-15 US US16/638,402 patent/US12297272B2/en active Active
- 2018-08-15 MX MX2020001707A patent/MX2020001707A/es unknown
- 2018-08-15 JP JP2020507675A patent/JP2020531002A/ja active Pending
- 2018-08-15 EP EP18846242.8A patent/EP3668536A4/en active Pending
-
2023
- 2023-09-06 AU AU2023226676A patent/AU2023226676B2/en active Active
-
2025
- 2025-08-22 AU AU2025220819A patent/AU2025220819A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531002A5 (cg-RX-API-DMAC7.html) | ||
| US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| JP7748393B2 (ja) | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 | |
| CN113038964B (zh) | 超长效胰岛素-fc融合蛋白及使用方法 | |
| US12351622B2 (en) | Modified product of Fc domain of antibody | |
| JP7231553B2 (ja) | Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用 | |
| JP5199876B2 (ja) | 一価ＩｇＧを生成するための方法 | |
| US10287336B2 (en) | Feline erythropoietin receptor agonists | |
| US20130121959A1 (en) | Il-22-fc and hepcidin activity | |
| JP2019511457A5 (cg-RX-API-DMAC7.html) | ||
| TW202444759A (zh) | Ａβ靶向蛋白及使用方法 | |
| EP4166574A1 (en) | Fusion protein containing erythropoietin polypeptide | |
| WO2005097998A2 (en) | Il-18 specific polypeptides and therapeutic uses thereof | |
| CN117999289A (zh) | 具有延长的半衰期的抗体和IgG融合蛋白 |